Product Showcase Sessions are short presentations held at the IASLC 2021 World Conference on Lung Cancer by exhibitors or sponsors. They are not sponsored or endorsed by the IASLC and are not part of the official IASLC accredited program.
All Product Showcase Sessions take place in the Product Showcase Theater on Virtual Platform from September 1, 2021, 15:00 MDT till December 17, 2021,15:00 MDT.
Description
Please join us to watch Dr Roy Decker share the PACIFIC Trial 5-Year Data update, as well as his perspective on its significance for healthcare professionals and patients. Also, stay tuned to watch Dr Roy Herbst discuss the clinical results from the ADAURA trial.
Speakers
Agenda
The product video will be available on the event platform starting September 20, 2021 till December 17, 2021.
Description
Please join this program to learn about:
Speaker
Description
This session will review how to identify RET fusion+ metastatic non-small cell lung cancer (mNSCLC) and provide an overview of an approved RET inhibitor for treatment. The overview will include clinical trial data, safety information, and dosing recommendations. This session will also review a hypothetical case of a patient with RET+ mNSCLC, from identification to management.
Speakers
Description
BI is committed to pushing innovation in cancer treatment. KRAS mutations are known drivers of lung cancer, and direct KRAS G12C inhibitors have shown significant clinial activity and favorable safety profile in patients with advanced NSCLC harboring KRAS G12C. BI is committed to tackling KRAS across a broad range of mutants through novel mechanisms including those that address all KRAS mutants directly, block KRAS activation, combine to block feedback or combine to block resistance.
Speakers
Agenda
Description
BI’s pipeline of immune-oncology treatments aim to make cancers more visible to the immune system by focusing on T-cell priming and immune modulation, and through intelligent combination approaches. The ultimate goal is to improve the efficacy of checkpoint inhibition and to enhance personalized medicine through novel therapies that are tailored to the patient’s tumor and can destroy it with minimal toxicity.
Speakers
Agenda
Description
Join our panelists to discuss: What are the outstanding questions regarding treatments in squamous NSCLC? What does recent real-world evidence reveal about clinical management of patients with squamous NSCLC? How can real-world evidence be used to inform treatment strategies for squamous NSCLC?
Speakers
Agenda
Description
Join G1 Therapeutics, Inc., a company focused on next-generation cancer therapies, as they review the current management of chemotherapy-induced myelosuppression (CIM). This presentation will highlight a new therapeutic approach to proactively help protect hematopoietic stem and progenitor cells in the bone marrow from chemotherapy-induced damage. Led by Dr. Mark Socinski, MD, the session will outline the burden and current treatment landscape of CIM and present important information about a novel treatment. Mechanism of action, safety and efficacy data, and dosing and administration information will be discussed.
Speaker
Agenda
Description
Objective:
Audience:
Direction:
Speakers
Agenda
Description
EGFR Exon 20 Insertion Mutations – Emerging Implications for the Management & Treatment of Metastatic Non-Small Cell Lung Cancer (NSCLC)
Agenda
Description
Circulating tumor DNA (ctDNA) is an emerging biomarker for early determination of molecular residual disease (MRD), treatment response, and recurrence. Join us for a discussion about ctDNA testing and how Signatera, a personalized, tumor-informed ctDNA assay is revolutionizing clinical decisions and trial design in solid tumors, including lung cancer.
Description
DetermaRx is a treatment stratification test to identify patients with Stage I and IIA non-squamous NSCLC who may benefit from adjuvant chemotherapy. DetermaRx is a 14-gene molecular stratification test that has been validated in over 1400 patients, and outperformed NCCN criteria in identifying patients at high risk for mortaility from stage IA, IB, and IIA non-squamous NSCLC. Oncocyte now offers DetermaRx+EGFR testing to provide a complete molecular testing solution in early-stage NSCLC, guiding treatment selection of targeted therapy and adjuvant chemotherapy.
Speakers
Agenda
Description
Dr. Todd Bauer, USA, speaks about a first-line treatment option for ALK+ metastatic non-small cell lung cancer (NSCLC). This presentation provides an overview of the efficacy and safety data for this treatment.
Speaker
Description
The Takeda WCLC Product Theatre presentation titled “ALUNBRIG® (brigatinib): A Treatment Option for Patients With Anaplastic Lymphoma Kinase (ALK)–Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)” will review a case study of a patient diagnosed with ALK-positive metastatic NSCLC and pivotal data from the ALTA-1L study of ALUNBRIG vs crizotinib in patients with ALK-positive metastatic NSCLC. Key systemic and intracranial efficacy and quality-of-life data on ALUNBRIG will be highlighted, together with a summary of the ALUNBRIG safety profile, warnings and precautions, drug interactions, and use in specific populations.
Speaker
Agenda
Description
Genomic testing represents the foundation of the precision oncology paradigm. Next-generation sequencing (NGS) is undoubtedly the technology of choice for effective multiple biomarker testing. This presentation will unravel the key implications of NGS testing for optimal patient clinical management. Prof. Lukas Bubendorf from the University Hospital of Basel will cover the current lung cancer biomarker landscape and associated best practices for appropriate molecular profiling using NGS in 2021.
Speaker
Agenda
Description
A lung pathologist, medical oncologist, thoractic surgeon and medical oncology lead nurse practitioner discuss the importance of biomarker testing in non-small cell lung cancer (NSCLC).
Speakers
Keep up to date with Conference News & Alerts.
Sign Up
#WCLC21
